Characteristics of Mycoplasma Genitalium Urogenital Infections in a Diverse Patient Sample from the United States: Results from the Aptima Mycoplasma Genitalium Evaluation Study (AMES)
Overview
Authors
Affiliations
Data from a large prospective multicenter clinical validation study of a nucleic acid amplification diagnostic test for were analyzed to describe the prevalence of infection, risk factors, and disease associations in female and male patients seeking care in diverse geographic regions of the United States. Among 1,737 female and 1,563 male participants, the overall prevalence of infection was 10.3% and was significantly higher in persons ages 15 to 24 years than in persons ages 35 to 39 years (for females, 19.8% versus 4.7% [odds ratio {OR} = 5.05; 95% confidence interval {CI} = 3.01 to 8.46]; for males, 16.5% versus 9.4% [OR = 1.91; 95% CI = 1.20 to 3.02]). The risk for infection was higher in black than in white participants (for females, 12.0% versus 6.8% [OR = 1.88; 95% CI = 1.30 to 2.72]; for males, 12.9% versus 6.9% [OR = 2.02; 95% CI = 1.38 to 2.96]) and higher in non-Hispanic than in Hispanic participants (for females, 11.2% versus 6.0% [OR = 1.97; 95% CI = 1.25 to 3.10]; for males, 11.6% versus 6.8% [OR = 1.80; 95% CI = 1.14 to 2.85]). Participants reporting urogenital symptoms had a significantly elevated risk of infection compared to that for asymptomatic individuals (for females, OR = 1.53 [95% CI = 1.09 to 2.14]; for males, OR = 1.42 [95% CI = 1.02 to 1.99]). Women diagnosed with vaginitis and cervicitis had a higher prevalence of infection than women without those diagnoses, although this was statistically significant only for vaginitis (for vaginitis, OR = 1.88 [95% CI = 1.37 to 2.58]; for cervicitis, OR = 1.42 [95% CI = 0.61 to 2.96]). A diagnosis of urethritis in men was also significantly associated with infection (OR = 2.97; 95% CI = 2.14 to 4.13). Few characteristics distinguished asymptomatic from symptomatic infections. These results from persons seeking care in the United States suggest that infection should be considered in young persons presenting with urogenital symptoms.
Schwebke J, Nyirjesy P, DSouza M, Getman D J Clin Microbiol. 2024; 62(9):e0081624.
PMID: 39140739 PMC: 11389145. DOI: 10.1128/jcm.00816-24.
Sukhija-Cohen A, Patani H, Robinson A, Santos M, Granados Y Open Forum Infect Dis. 2024; 11(8):ofae419.
PMID: 39113830 PMC: 11304595. DOI: 10.1093/ofid/ofae419.
Hakre S, Sanders-Buell E, Casimier R, OSullivan A, Peel S, Tovanabutra S Open Forum Infect Dis. 2024; 11(7):ofae407.
PMID: 39077051 PMC: 11285372. DOI: 10.1093/ofid/ofae407.
Clinical Updates in Sexually Transmitted Infections, 2024.
Hufstetler K, Llata E, Miele K, Quilter L J Womens Health (Larchmt). 2024; 33(6):827-837.
PMID: 38770770 PMC: 11270754. DOI: 10.1089/jwh.2024.0367.
Mullis C, Marlow K, Maity A, Fazzari M, Zingman B, Keller M Sex Transm Dis. 2023; 51(3):199-205.
PMID: 38100794 PMC: 10922512. DOI: 10.1097/OLQ.0000000000001911.